These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

271 related articles for article (PubMed ID: 23914021)

  • 21. Statins for primary prevention: problems with cardiovascular-risk estimation?
    Reiner Ž
    Nat Rev Cardiol; 2013 Sep; 10(9):547. PubMed ID: 23880954
    [No Abstract]   [Full Text] [Related]  

  • 22. Comparative benefits of statins in the primary and secondary prevention of major coronary events and all-cause mortality: a network meta-analysis of placebo-controlled and active-comparator trials.
    Naci H; Brugts JJ; Fleurence R; Tsoi B; Toor H; Ades AE
    Eur J Prev Cardiol; 2013 Aug; 20(4):641-57. PubMed ID: 23447425
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Statins: have we found the Holy Grail?
    Jeger R; Dieterle T
    Swiss Med Wkly; 2012; 142():w13515. PubMed ID: 22315166
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Statins for primary prevention: identifying low-risk individuals.
    Huang YL; Huang Y; Wu YX
    Nat Rev Cardiol; 2013 Sep; 10(9):547. PubMed ID: 23880953
    [No Abstract]   [Full Text] [Related]  

  • 25. [Therapeutic Strategies. Cardiovascular risk and dyslipidemia in elderly and women].
    Morales C; Royuela M
    Clin Investig Arterioscler; 2013; 25(3):146-50. PubMed ID: 23786854
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Statins in the management of dyslipidemias].
    Scheen AJ
    Rev Prat; 2011 Oct; 61(8):1120-6. PubMed ID: 22135981
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A Bayesian network meta-analysis of PCSK9 inhibitors, statins and ezetimibe with or without statins for cardiovascular outcomes.
    Khan SU; Talluri S; Riaz H; Rahman H; Nasir F; Bin Riaz I; Sattur S; Ahmed H; Kaluski E; Krasuski R
    Eur J Prev Cardiol; 2018 May; 25(8):844-853. PubMed ID: 29569492
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Treating Dyslipidemia for the Primary and Secondary Prevention of Stroke.
    Barkas F; Milionis H
    Semin Neurol; 2017 Jun; 37(3):286-293. PubMed ID: 28759910
    [No Abstract]   [Full Text] [Related]  

  • 29. Starting statins for primary prevention of cardiovascular disease.
    Tunstall-Pedoe H
    Heart; 2013 Nov; 99(21):1547-8. PubMed ID: 23878178
    [No Abstract]   [Full Text] [Related]  

  • 30. Statin adherence and risk of acute cardiovascular events among women: a cohort study accounting for time-dependent confounding affected by previous adherence.
    Lavikainen P; Helin-Salmivaara A; Eerola M; Fang G; Hartikainen J; Huupponen R; Korhonen MJ
    BMJ Open; 2016 Jun; 6(6):e011306. PubMed ID: 27259530
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Managing the dyslipidemia of metabolic syndrome: beyond statin therapy.
    Jialal I; Smith G
    Metab Syndr Relat Disord; 2012 Jun; 10(3):159-60. PubMed ID: 22568574
    [No Abstract]   [Full Text] [Related]  

  • 32. The efficiency of cardiovascular risk assessment: do the right patients get statin treatment?
    van Staa TP; Smeeth L; Ng ES; Goldacre B; Gulliford M
    Heart; 2013 Nov; 99(21):1597-602. PubMed ID: 23735939
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Prevalence and characteristics of lipid abnormalities in patients treated with statins in primary and secondary prevention in Spain. DYSIS-Spain Study].
    González-Juanatey JR; Millán J; Alegría E; Guijarro C; Lozano JV; Vitale GC
    Rev Esp Cardiol; 2011 Apr; 64(4):286-94. PubMed ID: 21411216
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Recommendations for management of dyslipidemia in 2016 in Switzerland].
    Aubert CE; Gencer B; Rodondi N
    Rev Med Suisse; 2016 Mar; 12(508):430-4. PubMed ID: 27089598
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prescription of Statins to Women Poses New Clinical Challenges.
    Pung M; Robishaw J; Pfeffer MA; Hennekens CH
    Am J Med; 2018 Oct; 131(10):1139-1140. PubMed ID: 29679537
    [No Abstract]   [Full Text] [Related]  

  • 36. Lipid-lowering therapy with statins for the primary and secondary prevention of cardiovascular disease.
    Lardizabal JA; Deedwania P
    Cardiol Clin; 2011 Feb; 29(1):87-103. PubMed ID: 21257102
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Editorial commentary: The long and winding road to follow dyslipidemia guidelines.
    Bonaventura A
    Trends Cardiovasc Med; 2024 Aug; 34(6):379-380. PubMed ID: 37673292
    [No Abstract]   [Full Text] [Related]  

  • 38. Time to improve statin prescription guidelines in low-risk patients?
    Balder JW; de Vries JK; Mulder DJ; Kamphuisen PW
    Eur J Prev Cardiol; 2017 Jul; 24(10):1064-1070. PubMed ID: 28429651
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Postponement of cardiovascular outcomes by statin use: A systematic review and meta-analysis of randomized clinical trials.
    Hansen MR; Hróbjartsson A; Pottegård A; Damkier P; Madsen KG; Pareek M; Olesen M; Hallas J
    Basic Clin Pharmacol Toxicol; 2021 Feb; 128(2):286-296. PubMed ID: 32896109
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efficacy of statin treatment based on cardiovascular outcomes in elderly patients: a standard meta-analysis and Bayesian network analysis.
    Zhai C; Hou K; Li R; Hu Y; Zhang J; Zhang Y; Wang L; Zhang R; Cong H
    J Int Med Res; 2020 Jun; 48(6):300060520926349. PubMed ID: 32529863
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.